Enrofloxacin

Enrofloxacin

Systematic (IUPAC) name
1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolonecarboxylic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	B3 (AU) C (US)
Legal status	Prescription Only (S4) (AU) POM (UK)
Routes	Oral, subcutaneous injection, topical (ear drops)
Pharmacokinetic data
Bioavailability	80% in dogs, 65-75% in sheep
Metabolism	Renal and non-renal
Half-life	4–5 hours in dogs, 6 hours in cats, 1.5 - 4.5 hours in sheep.
Excretion	Renal
Identifiers
CAS number	93106-60-6
ATCvet code	QJ01MA90
PubChem	CID 71188
ChemSpider	64326 Y
UNII	3DX3XEK1BN Y
KEGG	D02473 Y
ChEBI	CHEBI:35720
ChEMBL	CHEMBL15511 Y
Chemical data
Formula	C19H22FN3O3
Mol. mass	359.4
SMILES O=C(O)\C3=C\N(c2cc(N1CCN(CC)CC1)c(F)cc2C3=O)C4CC4
InChI InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26) Y Key:SPFYMRJSYKOXGV-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Enrofloxacin is a fluoroquinolone antibiotic sold by the Bayer Corporation under the trade name Baytril. Enrofloxacin is currently FDA-approved for treatment of individual pets and domestic animals in the United States. In September 2005, the FDA withdrew approval of Baytril for use in water to treat flocks of poultry, as this practice was noted to promote the evolution of fluoroquinolone-resistant strains of the bacterium Campylobacter, a human pathogen. Fluoroquinolones such as ciprofloxacin are widely used in the treatment of human disease.

It is a bactericidal agent. The bactericidal activity of enrofloxacin is concentration-dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. Enrofloxacin has demonstrated a significant post-antibiotic effect for both Gram-negative and Gram-positive bacteria and is active in both stationary and growth phases of bacterial replication.

Activity

Enrofloxacin is a synthetic chemotherapeutic agent from the class of the fluoroquinolone carboxylic acid derivatives. It has antibacterial activity against a broad spectrum of Gram-negative and Gram-positive bacteria. Its mechanism of action is not thoroughly understood, but it is believed to act by inhibiting bacterial DNA gyrase (a type-II topoisomerase), thereby preventing DNA supercoiling and DNA synthesis. It is effective against:

• Pseudomonas aeruginosa
• Klebsiella
• Escherichia coli
• Enterobacter
• Campylobacter
• Shigella
• Salmonella
• Aeromonas
• Haemophilus
• Proteus
• Yersinia
• Serratia
• Vibrio
• Brucella
• Chlamydia trachomatis
• Staphylococcus (including penicillinase-producing and methicillin-resistant strains)
• Mycoplasma
• Mycobacterium

Variable activity against:

• Streptococcus

Ineffective against:

• anaerobes

Contraindications/precautions

High drug resistance.

Adverse effects/warnings

• Permanent blindness and vision loss have been reported with fluoroquinolones, including enrofloxacin. Enrofloxacin was banned for poultry use in 2005

Baytril should not be used in rapidly-growing animals (for example dogs under 12 months - 18 months in large breeds, or kittens under 8 weeks) as it causes abnormalities in the development of articular cartilage.^{[citation needed]}

Overdosage/acute toxicity

It is unlikely that an acute overdose of either compound would result in symptoms more serious than either anorexia or vomiting, but the adverse effects noted above could occur. Dogs receiving 10 times the labeled dosage rate of enrofloxacin for at least 14 days developed only vomiting and anorexia. Death did occur in some dogs when fed 25 times the labeled rate for 11 days, however.

• Oral LD₅₀: greater than 5000 mg/kg
• Dermal LD₅₀: greater than 2000 mg/kg
• Inhalation LD₅₀: greater than 3547 mg/m3 (4-hour exposure)
• Eye effects: irritant; reversible in less than 7 days. In cats, it can produce sudden onset blindness when administered by injection, as it is retinotoxic.

See also

• Fluoroquinolone toxicity
• Fluoroquinolone